Literature DB >> 19145465

mTOR phosphorylated at S2448 binds to raptor and rictor.

M Rosner1, N Siegel, A Valli, C Fuchs, M Hengstschläger.   

Abstract

In mammalian cells, the mammalian target of rapamycin (mTOR) forms an enzyme complex with raptor (together with other proteins) named mTOR complex 1 (mTORC1), of which a major target is the p70 ribosomal protein S6 kinase (p70S6K). A second enzyme complex, mTOR complex 2 (mTORC2), contains mTOR and rictor and regulates the Akt kinase. Both mTORC1 and mTORC2 are regulated by phosphorylation, complex formation and localization. So far, the role of p70S6K-mediated mTOR S2448 phosphorylation has not been investigated in detail. Here, we report that endogenous mTOR phosphorylated at S2448 binds to both, raptor and rictor. Experiments with chemical inhibitors of the mTOR kinase and of the phosphatidylinositol-3-kinase revealed that downregulation of mTOR S2448 phosphorylation correlates with decreased mTORC1 activity but can occur decoupled of effects on mTORC2 activity. In addition, we found that the correlation of the mTOR S2448 phosphorylation status with mTORC1 activity is not a consequence of effects on the assembly of mTOR protein and raptor. Our data allow new insights into the role of mTOR phosphorylation for the regulation of its kinase activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19145465     DOI: 10.1007/s00726-008-0230-7

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  69 in total

1.  Human cytomegalovirus induces multiple means to combat reactive oxygen species.

Authors:  Carisa Tilton; Amy J Clippinger; Tobi Maguire; James C Alwine
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.

Authors:  Pamela A Smith; David Merritt; Leah Barr; David A Thorley-Lawson
Journal:  Genes Cancer       Date:  2011-11

Review 3.  mTOR function and therapeutic targeting in breast cancer.

Authors:  Stephen H Hare; Amanda J Harvey
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 4.  Regulation of mTORC1 by PI3K signaling.

Authors:  Christian C Dibble; Lewis C Cantley
Journal:  Trends Cell Biol       Date:  2015-07-06       Impact factor: 20.808

5.  Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation.

Authors:  Noha M Shawky; Lakshman Segar
Journal:  Pharmacol Res       Date:  2017-02-14       Impact factor: 7.658

6.  Prediction of functional phosphorylation sites by incorporating evolutionary information.

Authors:  Shen Niu; Zhen Wang; Dongya Ge; Guoqing Zhang; Yixue Li
Journal:  Protein Cell       Date:  2012-07-16       Impact factor: 14.870

7.  Leptin signaling and Alzheimer's disease.

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 8.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

Review 9.  Common corruption of the mTOR signaling network in human tumors.

Authors:  S Menon; B D Manning
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

10.  Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation.

Authors:  Ulrike Bruning; Francisco Morales-Rodriguez; Joanna Kalucka; Jermaine Goveia; Federico Taverna; Karla C S Queiroz; Charlotte Dubois; Anna Rita Cantelmo; Rongyuan Chen; Stefan Loroch; Evy Timmerman; Vanessa Caixeta; Katarzyna Bloch; Lena-Christin Conradi; Lucas Treps; An Staes; Kris Gevaert; Andrew Tee; Mieke Dewerchin; Clay F Semenkovich; Francis Impens; Birgit Schilling; Eric Verdin; Johannes V Swinnen; Jordan L Meier; Rhushikesh A Kulkarni; Albert Sickmann; Bart Ghesquière; Luc Schoonjans; Xuri Li; Massimiliano Mazzone; Peter Carmeliet
Journal:  Cell Metab       Date:  2018-08-23       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.